<DOC>
	<DOCNO>NCT02163707</DOCNO>
	<brief_summary>Psilocybin naturally occur psychedelic compound produce 200 specie mushroom , collectively know psilocybin mushroom . Psilocybin ( 4-phosphoroyloxy-N , N-dimethyltryptamine ) hallucinogenic tryptamine first isolate Psilocybe mushroom 1957 . The objective Phase I clinical trial determine pharmacokinetics oral dos psilocybin normal , healthy adult . The study perform support Phase II Phase III study psilocybin treatment refractory anxiety associate incurable cancer , well possible indication . Psilocybin present FDA-approved drug .</brief_summary>
	<brief_title>UW Psilocybin Pharmacokinetics Study</brief_title>
	<detailed_description>The primary objective clinical trial determine pharmacokinetics extemporaneous oral formulation psilocybin normal , healthy adult . This study intend add exist body modern clinical research psilocybin support future multi-institutional Phase III clinical trial seek decrease anxiety depression patient incurable cancer . The long-term goal research submit successful new drug application psilocybin FDA . Subjects initially take one 0.3 mg/kg ( approximately 20mg/70kg ) oral dose psilocybin initiate eight hour chaperon outpatient experience . After eight hour outpatient sampling , subject transport across street UW Institute Clinical Translational Research Clinical Research Unit ( ICTR CRU ) overnight stay additional blood urine sample . Pre- post-treatment psychologic preparation debrief interview require . A minimum four week first dose , subject receive second oral dose psilocybin high dose 0.45 mg/kg ( approximately 30 mg/70 kg ) . This dose take place attend , structure setting time blood urine sample obtain School Pharmacy ( 0-8 hour ) UW Clinical Research Unit ( 8-24 hour ) . A minimum four week second dose , subject receive third oral dose psilocybin high dose 0.6 mg/kg ( approximately 40 mg/70 kg ) . This dose take place attend , structure setting time blood urine sample obtain School Pharmacy ( 0-8 hour ) UW Clinical Research Unit ( 8-24 hour ) . 12-lead ECGs obtain specified time point treatment period . Throughout duration drug action dose participant attend two trained monitor , physician available entire 24 hour treatment sample period . Subjects administer first dose decline receive subsequent dos remain evaluable . At time active study participation end .</detailed_description>
	<mesh_term>Psilocybine</mesh_term>
	<criteria>Aged 21 80 year Able read , speak , understand spoken English Selfreport least one prior positive hallucinogen drug experience include meaningful altered state consciousness . Hallucinogenic substance include psilocybin , LSD , classic hallucinogen . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 base upon CRU NP study physician physical exam , indicate subject fully function . A woman childbearing potential must agree practice effective mean birth control participation clinical trial , include 90 day followup last psilocybin dose . Birth control method write agreement practice method throughout duration study document Medical History Case Report Form . Effective contraception define regular use one following : Established use oral , injected , implanted hormonal method contraception Placement intrauterine device ( IUD ) intrauterine system ( IUS ) Barrier method : Condom Occlusive cap use spermicide female sterilization/hysterectomy ( documentation surgery ) postmenopausal ( &gt; 12 month since last menses time screen ) Male sterilization ( postvasectomy documentation ) True abstinence Ability willingness adhere study requirement , include attend study visit , preparatory followup session , complete study evaluation . Agree refrain use psychoactive drug , include alcoholic beverage tobacco , within 24 hour drug administration . The exception caffeine . Participants require nonsmoker . Estimated creatinine clearance &lt; 30 ml/min , use Cockcroft Gault equation actual body weight . Clinically significant abnormal chemistry hematologic laboratory result ( screen Complete Blood Count Differential Comprehensive Metabolic Panel ) , use UWHC core lab reference interval . Females childbearing potential positive urine pregnancy screen day first treatment . Clinically significant abnormality physical examination . Inadequately treated hypertension ( systolic blood pressure &gt; 140 mmHg diastolic blood pressure &gt; 90 mmHg ) . Personal history primary psychotic disorder ( unless substanceinduced due medical condition ) , bipolar affective disorder Type I Type II , schizophrenia . First seconddegree family history primary psychotic disorder , bipolar affective disorder Type I , bipolar affective disorder Type II , schizophrenia . Substance abuse dependency within past five year . Suicidal ideation attempt within past 30 day and/or prior suicidal ideation/attempt study physician PI feel make participant unsuitable study . Urine drug test contain nonprescribed drug abuse ( nonprescribed opioids , benzodiazepine , amphetamine , phencyclidine , cocaine ) screen day first treatment . Urine cannabinoid concentration &gt; 50 ng/ml suggest heavy marijuana use , threshold exclude potential subject . Current use monoamine oxidase inhibitor dopaminergic antagonist . Any prohibited agent must stop least 5x elimination halflife specific drug . Subject local support person available 24 hour treatment observation period . Concurrent recent ( within 5 year ) history major depression , obsessivecompulsive disorder , panic disorder , anorexia nervosa , bulimia nervosa . Poor venous access . Known acute coronary syndrome angina . Evidence ischemic disease ventricular arrhythmia screen ECG . Cardiac conduction defect screen ECG . Cardiac transplantation determine selfreport review medical history . Lactose intolerance ( excipient psilocybin capsule ) Type I insulindependent Type II diabetes . Prescription medicine require dose 8 hour drug action . Current recent ( past 5 year ) seizure disorder determine selfreport medical history physical exam . Chronic frequent migraine . Regular frequent use benzodiazepine . Attention Deficit Hyperactivity Disorder ( ADHD ) Attention Deficit Disorder ( ADD ) . Regular frequent use stimulant . Generalized Anxiety Disorder ( GAD ) . PostTraumatic Stress Disorder ( PTSD ) . Neuroleptic medication . Any physical psychological symptom , base clinical judgment study physician and/or psychologist , would make participant unsuitable study . Any use medication ( ) , base clinical judgment study physician , would make participant unsuitable study . Any finding ( ) , base screening process , PI feel make participant unsuitable study .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Psilocybin</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>